1
|
Bryushkova EA, Mushenkova NV, Turchaninova MA, Lukyanov DK, Chudakov DM, Serebrovskaya EO. B cell clonality in cancer. Semin Immunol 2024; 72:101874. [PMID: 38508089 DOI: 10.1016/j.smim.2024.101874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Revised: 01/05/2024] [Accepted: 01/05/2024] [Indexed: 03/22/2024]
Abstract
Carcinogenesis in the process of long-term co-evolution of tumor cells and immune environment essentially becomes possible due to incorrect decisions made, remembered, and reproduced by the immune system at the level of clonal populations of antigen-specific T- and B-lymphocytes. Tumor-immunity interaction determines the nature of such errors and, consequently, delineates the possible ways of successful immunotherapeutic intervention. It is generally recognized that tumor-infiltrating B cells (TIL-B) can play both pro-tumor and anti-tumor roles. However, the exact mechanisms that determine the contribution of clonal B cell lineages with different specificities and functions remain largely unclear. This is due to the variability of cancer types, the molecular heterogeneity of tumor cells, and, to a large extent, the individual pattern of each immune response. Further progress requires detailed investigation of the functional properties and phenotypes of clonally heterogeneous B cells in relation to their antigenic specificities, which determine the functionality of both effector B lymphocytes and immunoglobulins produced in the tumor environment. Based on a real understanding of the role of clonal antigen-specific populations of B lymphocytes in the tumor microenvironment, we need to learn how to develop new methods of targeted immunotherapy, as well as adapt existing treatment options to the specific needs of different patients and patient subgroups. In this review, we will cover B cells functional diversity and their multifaceted roles in the tumor environment.
Collapse
Affiliation(s)
- E A Bryushkova
- Institute of Translational Medicine, Pirogov Russian National Research Medical University, Moscow, Russia; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia; Department of Molecular Biology, Lomonosov Moscow State University, Moscow, Russia
| | - N V Mushenkova
- Institute of Translational Medicine, Pirogov Russian National Research Medical University, Moscow, Russia; Unicorn Capital Partners, Moscow, Russia
| | - M A Turchaninova
- Institute of Translational Medicine, Pirogov Russian National Research Medical University, Moscow, Russia; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia
| | - D K Lukyanov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia; Center of Life Sciences, Skolkovo Institute of Science and Technology, Moscow, Russia
| | - D M Chudakov
- Institute of Translational Medicine, Pirogov Russian National Research Medical University, Moscow, Russia; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia; Center of Life Sciences, Skolkovo Institute of Science and Technology, Moscow, Russia; Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
| | - E O Serebrovskaya
- Institute of Translational Medicine, Pirogov Russian National Research Medical University, Moscow, Russia; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia; Current position: Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany
| |
Collapse
|
2
|
Zheng Y, Wang Y, Lu Z, Wan J, Jiang L, Song D, Wei C, Gao C, Shi G, Zhou J, Fan J, Ke A, Zhou L, Cai J. PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti-PD-1 Immunotherapy. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2023; 10:e2301928. [PMID: 37705495 PMCID: PMC10582428 DOI: 10.1002/advs.202301928] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/24/2023] [Revised: 07/12/2023] [Indexed: 09/15/2023]
Abstract
The combination of immunotherapy and molecular targeted therapy exhibits promising therapeutic efficacy in hepatocellular carcinoma (HCC), but the underlying mechanism is still unclear. Here, phosphoglycerate mutase 1 (PGAM1) is identified as a novel immunometabolic target by using a bioinformatic algorithm based on multiple HCC datasets. PGAM1 is highly expressed in HCC and associated with a poor prognosis and a poor response to immunotherapy. In vitro and in vivo experiments indicate that targeting PGAM1 inhibited HCC cell growth and promoted the infiltration of CD8+ T-cells due to decreased enzymatic activity. Mechanistically, inhibition of PGAM1 promotes HCC cell ferroptosis by downregulating Lipocalin (LCN2) by inducing energy stress and ROS-dependent AKT inhibition, which can also downregulate Programmed death 1-ligand 1 (PD-L1). Moreover, an allosteric PGAM1 inhibitor (KH3) exhibits good antitumor effects in patient-derived xenograft (PDX) models and enhanced the efficacy of anti-PD-1 immunotherapy in subcutaneous and orthotopic HCC models. Taken together, the findings demonstrate that PGAM1 inhibition exerts an antitumor effect by promoting ferroptosis and CD8+ T-cell infiltration and can synergize with anti-PD-1 immunotherapy in HCC. Targeting PGAM1 can be a promising new strategy of "killing two birds with one stone" for HCC treatment.
Collapse
Affiliation(s)
- Yimin Zheng
- Department of Liver Surgery and TransplantationLiver Cancer InstituteZhongshan HospitalFudan University; Key Laboratory of Carcinogenesis and Cancer InvasionShanghai Key Laboratory of Organ TransplantationZhongshan HospitalShanghai200032P. R. China
| | - Yining Wang
- Department of Liver Surgery and TransplantationLiver Cancer InstituteZhongshan HospitalFudan University; Key Laboratory of Carcinogenesis and Cancer InvasionShanghai Key Laboratory of Organ TransplantationZhongshan HospitalShanghai200032P. R. China
| | - Zhou Lu
- Department of Liver Surgery and TransplantationLiver Cancer InstituteZhongshan HospitalFudan University; Key Laboratory of Carcinogenesis and Cancer InvasionShanghai Key Laboratory of Organ TransplantationZhongshan HospitalShanghai200032P. R. China
| | - Jinkai Wan
- Shanghai Key Laboratory of Medical EpigeneticsInternational Co‐laboratory of Medical Epigenetics and MetabolismMinistry of Science and TechnologyInstitutes of Biomedical SciencesFudan UniversityShanghai200032P. R. China
| | - Lulu Jiang
- Department of Medicinal ChemistrySchool of PharmacyFudan UniversityShanghai201203P. R. China
| | - Danjun Song
- Department of Interventional TherapyThe Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)Institute of Basic Medicine and Cancer (IBMC)Chinese Academy of SciencesHangzhouZhejiang310022P. R. China
| | - Chuanyuan Wei
- Department of Liver Surgery and TransplantationLiver Cancer InstituteZhongshan HospitalFudan University; Key Laboratory of Carcinogenesis and Cancer InvasionShanghai Key Laboratory of Organ TransplantationZhongshan HospitalShanghai200032P. R. China
| | - Chao Gao
- Department of Liver Surgery and TransplantationLiver Cancer InstituteZhongshan HospitalFudan University; Key Laboratory of Carcinogenesis and Cancer InvasionShanghai Key Laboratory of Organ TransplantationZhongshan HospitalShanghai200032P. R. China
| | - Guoming Shi
- Department of Liver Surgery and TransplantationLiver Cancer InstituteZhongshan HospitalFudan University; Key Laboratory of Carcinogenesis and Cancer InvasionShanghai Key Laboratory of Organ TransplantationZhongshan HospitalShanghai200032P. R. China
| | - Jian Zhou
- Department of Liver Surgery and TransplantationLiver Cancer InstituteZhongshan HospitalFudan University; Key Laboratory of Carcinogenesis and Cancer InvasionShanghai Key Laboratory of Organ TransplantationZhongshan HospitalShanghai200032P. R. China
| | - Jia Fan
- Department of Liver Surgery and TransplantationLiver Cancer InstituteZhongshan HospitalFudan University; Key Laboratory of Carcinogenesis and Cancer InvasionShanghai Key Laboratory of Organ TransplantationZhongshan HospitalShanghai200032P. R. China
| | - Aiwu Ke
- Department of Liver Surgery and TransplantationLiver Cancer InstituteZhongshan HospitalFudan University; Key Laboratory of Carcinogenesis and Cancer InvasionShanghai Key Laboratory of Organ TransplantationZhongshan HospitalShanghai200032P. R. China
| | - Lu Zhou
- Department of Medicinal ChemistrySchool of PharmacyFudan UniversityShanghai201203P. R. China
| | - Jiabin Cai
- Department of Liver Surgery and TransplantationLiver Cancer InstituteZhongshan HospitalFudan University; Key Laboratory of Carcinogenesis and Cancer InvasionShanghai Key Laboratory of Organ TransplantationZhongshan HospitalShanghai200032P. R. China
| |
Collapse
|
3
|
Ash MK, Bhimalli PP, Cho BK, Mattamana BB, Gambut S, Tarhoni I, Fhied CL, Reyes AF, Welninski SJ, Arivalagan J, Negrão F, Goel R, Beck TL, Hope TJ, Sha BE, Goo YA, Al-Harthi L, Mamede JI, Borgia JA, Kelleher NL, Schneider JR. Bulk IgG glycosylation predicts COVID-19 severity and vaccine antibody response. Cell Rep 2022; 41:111799. [PMID: 36493786 PMCID: PMC9678812 DOI: 10.1016/j.celrep.2022.111799] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2022] [Revised: 10/13/2022] [Accepted: 11/16/2022] [Indexed: 11/23/2022] Open
Abstract
Although vaccination efforts have expanded, there are still gaps in our understanding surrounding the immune response to SARS-CoV-2. Measuring IgG Fc glycosylation provides insight into an infected individual's inflammatory state, among other functions. We set out to interrogate bulk IgG glycosylation changes from SARS-CoV-2 infection and vaccination, using plasma from mild or hospitalized COVID-19 patients, and from vaccinated individuals. Inflammatory glycans are elevated in hospitalized COVID-19 patients and increase over time, while mild patients have anti-inflammatory glycans that increase over time, including increased sialic acid correlating with RBD antibody levels. Vaccinated individuals with low RBD antibody levels and low neutralization have the same IgG glycan traits as hospitalized COVID-19 patients. In addition, a small vaccinated cohort reveals a decrease in inflammatory glycans associated with peak IgG concentrations and neutralization. This report characterizes the bulk IgG glycome associated with COVID-19 severity and vaccine responsiveness and can help guide future studies into SARS-CoV-2 protective immunity.
Collapse
Affiliation(s)
- Michelle K. Ash
- Department of Microbial Pathogens & Immunity, Rush University Medical Center, Cohn Research Building, 1735 W. Harrison St., Chicago, IL 60612, USA
| | - Pavan P. Bhimalli
- Department of Microbial Pathogens & Immunity, Rush University Medical Center, Cohn Research Building, 1735 W. Harrison St., Chicago, IL 60612, USA
| | - Byoung-Kyu Cho
- Proteomics Center of Excellence, Northwestern University, Evanston, IL, USA
| | | | - Stéphanie Gambut
- Department of Microbial Pathogens & Immunity, Rush University Medical Center, Cohn Research Building, 1735 W. Harrison St., Chicago, IL 60612, USA
| | - Imad Tarhoni
- Department of Anatomy & Cell Biology, Rush University Medical Center, Chicago, IL, USA
| | - Cristina L. Fhied
- Department of Anatomy & Cell Biology, Rush University Medical Center, Chicago, IL, USA
| | - Anjelica F. Reyes
- Department of Microbial Pathogens & Immunity, Rush University Medical Center, Cohn Research Building, 1735 W. Harrison St., Chicago, IL 60612, USA
| | - Samantha J. Welninski
- Department of Microbial Pathogens & Immunity, Rush University Medical Center, Cohn Research Building, 1735 W. Harrison St., Chicago, IL 60612, USA
| | - Jaison Arivalagan
- Proteomics Center of Excellence, Northwestern University, Evanston, IL, USA
| | - Fernanda Negrão
- Proteomics Center of Excellence, Northwestern University, Evanston, IL, USA
| | - Renu Goel
- Proteomics Center of Excellence, Northwestern University, Evanston, IL, USA,Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - Todd L. Beck
- Statistics Core, Rush University Medical Center, Chicago, IL, USA
| | - Thomas J. Hope
- Department of Biomedical Engineering, Northwestern University, Chicago, IL, USA,Department of Cell & Developmental Biology, Northwestern University, Chicago, IL, USA,Department of Obstetrics & Gynecology, Northwestern University, Chicago, IL, USA,Feinberg School of Medicine, Northwestern University, Chicago, IL, USA,Chemistry of Life Processes Institute, Northwestern University, Chicago, IL, USA
| | - Beverly E. Sha
- Division of Infectious Diseases, Rush University Medical Center, Chicago, IL, USA
| | - Young Ah Goo
- Proteomics Center of Excellence, Northwestern University, Evanston, IL, USA
| | - Lena Al-Harthi
- Department of Microbial Pathogens & Immunity, Rush University Medical Center, Cohn Research Building, 1735 W. Harrison St., Chicago, IL 60612, USA
| | - João I. Mamede
- Department of Microbial Pathogens & Immunity, Rush University Medical Center, Cohn Research Building, 1735 W. Harrison St., Chicago, IL 60612, USA
| | - Jeffrey A. Borgia
- Department of Anatomy & Cell Biology, Rush University Medical Center, Chicago, IL, USA,Department of Pathology, Rush University Medical Center, Chicago, IL, USA
| | - Neil L. Kelleher
- Proteomics Center of Excellence, Northwestern University, Evanston, IL, USA,Department of Chemistry, Northwestern University, Chicago, IL, USA,Department of Molecular Biosciences, Northwestern University, Chicago, IL, USA,Feinberg School of Medicine, Northwestern University, Chicago, IL, USA,Chemistry of Life Processes Institute, Northwestern University, Chicago, IL, USA
| | - Jeffrey R. Schneider
- Department of Microbial Pathogens & Immunity, Rush University Medical Center, Cohn Research Building, 1735 W. Harrison St., Chicago, IL 60612, USA,Corresponding author
| |
Collapse
|
4
|
Zhang M, Song J, Yang H, Jin F, Zheng A. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis. Acta Oncol 2022; 61:1105-1115. [PMID: 35939538 DOI: 10.1080/0284186x.2022.2106795] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
Abstract
OBJECTIVE Triple-negative breast cancer (TNBC) is a subtype of breast cancer with a poor prognosis that seriously threatens women's health. There is still a lack of effective therapeutic targets for TNBC treatment. We conducted a meta-analysis to evaluate the efficacy and safety of programmed cell death protein 1 (PD-1)/programmed death protein ligand 1 (PD-L1) inhibitors in combination with chemotherapy for TNBC patients. METHODS We searched PubMed, EMBASE, Cochrane Library, and Web of Science for randomized controlled trials (RCTs) related to PD-1/PD-L1 inhibitors combined with chemotherapy. Literature conforming to the research content was identified according to the inclusion and exclusion criteria. The endpoints of efficacy were pathological complete response (pCR), event-free survival (EFS), progression-free survival (PFS), and overall survival (OS). Safety outcomes included adverse events (AEs) of any grade, AEs of grade ≥3, serious AEs, and the incidence of various AEs. We obtained odds ratios (OR), hazard ratio (HR), and 95% confidence interval (CI) for the included studies. Data analysis was performed using Review Manager software (version 5.3). RESULTS A total of 4468 patients from eight RCTs were analyzed. PD-1/PD-L1 inhibitors in combination with chemotherapy significantly improved pCR (OR, 1.59; 95% CI, 1.28 - 1.98, p < 0.0001), EFS (HR, 0.66; 95% CI, 0.48 - 0.91, p = 0.01), and OS (HR, 0.72; 95% CI, 0.52 - 0.99, p = 0.05) in patients with TNBC compared to chemotherapy alone or placebo in combination with chemotherapy. Furthermore, we found that the pCR rate was almost identical in the PD-L1 positive group (OR, 1.65; 95% CI, 1.26 - 2.16, p = 0.0002) and the PD-L1 negative group (OR, 1.56; 95% CI, 1.04 - 2.33, p = 0.03). Among patients with advanced-stage TNBC, PFS (HR, 0.82; 95% CI, 0.74 - 0.90, p < 0.0001) was longer in the combination therapy group than in the chemotherapy group. There were no statistically significant differences between the experimental and control groups in OS (HR, 1.03; 95% CI, 0.74 - 1.42, p = 0.87). In terms of safety, we found that the combination therapy group had a significantly higher incidence of hyperthyroidism in patients with early and advanced TNBC (OR, 5.76; 95% CI, 2.38 - 13.95, p = 0.0001) (OR, 7.86; 95% CI, 2.65 - 23.29, p = 0.0002). CONCLUSIONS The combination of PD-1/PD-L1 inhibitors and chemotherapy could improve the survival and prognosis of patients with early and advanced TNBC. Combination treatment may be harmful to the thyroid; therefore, active surveillance and regular follow-up are necessary during treatment.
Collapse
Affiliation(s)
- Meilin Zhang
- Department of Breast Surgery, the First Affiliated Hospital of China Medical University, Shenyang, China
| | - Jian Song
- Department of Breast Surgery, the First Affiliated Hospital of China Medical University, Shenyang, China
| | - Hongguang Yang
- Department of Burn Plastic Surgery, Chaoyang Central Hospital, Chaoyang, China
| | - Feng Jin
- Department of Breast Surgery, the First Affiliated Hospital of China Medical University, Shenyang, China
| | - Ang Zheng
- Department of Breast Surgery, the First Affiliated Hospital of China Medical University, Shenyang, China
| |
Collapse
|